237 related articles for article (PubMed ID: 26619834)
1. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y; Ogura M; Tobinai K; Ando K; Suzuki T; Watanabe T; Ohmachi K; Uchida T; Hanson ME; Tanaka Y; Koh Y; Shimamoto T; Hotta T
Int J Hematol; 2016 Jan; 103(1):25-33. PubMed ID: 26619834
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
[TBL] [Abstract][Full Text] [Related]
3. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
5. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K
Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Deming DA; Ninan J; Bailey HH; Kolesar JM; Eickhoff J; Reid JM; Ames MM; McGovern RM; Alberti D; Marnocha R; Espinoza-Delgado I; Wright J; Wilding G; Schelman WR
Invest New Drugs; 2014 Apr; 32(2):323-9. PubMed ID: 24114123
[TBL] [Abstract][Full Text] [Related]
9. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
Brown S; Pawlyn C; Tillotson AL; Sherratt D; Flanagan L; Low E; Morgan GJ; Williams C; Kaiser M; Davies FE; Jenner MW;
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):154-161.e3. PubMed ID: 33478922
[TBL] [Abstract][Full Text] [Related]
11. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Voorhees PM; Gasparetto C; Moore DT; Winans D; Orlowski RZ; Hurd DD
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):424-432. PubMed ID: 28655599
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
Weber DM; Graef T; Hussein M; Sobecks RM; Schiller GJ; Lupinacci L; Hardwick JS; Jagannath S
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):319-24. PubMed ID: 23040438
[TBL] [Abstract][Full Text] [Related]
13. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
14. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
[No Abstract] [Full Text] [Related]
15. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Mazumder A; Vesole DH; Jagannath S
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):149-51. PubMed ID: 20371450
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma.
Kusumoto S; Sunami K; Inagaki M; Iida S
Int J Hematol; 2015 Jun; 101(6):578-84. PubMed ID: 25749662
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
